Table 3.

Perinatal Soy/Isoflavone Administration.

Species	Isoflavone Diet/Timing	Tumor Inducer	Main Finding	Refs
rat	250 mg daidzein/kg diet 2 week prior to mating-weaning	1 oral dose, 40 mg DMBA at PND50	No significant differences in tumor onset or incidence	[97]
rat	25 or 250 mg genistein/kg diet conception-weaning	1 oral dose, 80 mg/kg DMBA at PND50	Tumor multiplicity reduced in isoflavone group	[98]
rat	20 ug genistein injected on PND7, 10, 14, 17 and 20	1 injection, 10 mg DMBA at PND45	No significant effect on tumor latency or incidence but multiplicity and growth rate significantly lower in genistein group vs control group	[99]
rats	SPI, gestation day 4-EOS	1 injection of 50 mg/kg body weight NMU at PND51	No significant differences in tumor incidence but multiplicity significantly reduced	[94]
mice	0, 18, 90 or 270 mg/kg Prevastein (46.19% wt/wt isoflavones), conception-weaning	MMTV-neu on normal or high fat diet	No significant difference in tumor incidence but tumor multiplicity and size significantly increased in medium and high isoflavone group	[91]
mice	90 mg/kg Prevastein (46.19% wt/wt isoflavones) 2 weeks prior to mating-weaning	MMTV-neu on high fat diet with either corn oil of fish oil	No differences in tumor incidence or onset	[96]